Pharmaceuticals & Biotech U.S. Community

1. Cybin's Intellectual Property : Cybin has over 70 granted patents and 220 patent applications pending across multiple patent families.

Catalysts ◦ Strong position in the GLP-1 drug market , leading with Ozempic for diabetes and Wegovy for obesity. These products have driven significant growth.

AI Driven Drug Discovery/Absci leverages Ai and synthetic biology to revoltionize drug development, reducing costs and timelines, giving them a significant edge in the biotech sector Scalable Platform / Their technology platfrom is highly scalable, improving efficiency with each new project. This makes Absci increasingly competitive as the platform matures.

Catalysts Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u $22,999.80 Ingrezza@ Ingrezza (valbenazine) costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength. INGREZZA Capsule 40 MG $310.80 INGREZZA SPRINKLE Capsule 40 MG $310.80 Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Summary CD388 is a universal long-lasting influenza drug against all seasonal and pandemic influenza viruses in a phase 2b clinical trial. CD388 is not a vaccine but would provide 6 months of protection.

AstraZeneca PLC (AZN) is a prominent player in the pharmaceutical industry, with a diverse portfolio and a strong focus on innovation. Has recently demonstrated robust financial performance, with notable developments that may influence its market position over the next 1-3 years.

Kyverna has the most experienced and proven leadership team to bring CAR-T products to market (Former Kite exectuvies running the top positons and holding board positions) of whom have experience in this new field in scaling manufacturing and marketing these products. Kyverna also has an ample funding beyond most of its peers with a runway well into 3 years without additional fundraising or milestone payments.

11-NOV-2024 Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25) Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9, P/E24 = 44.6, P/S25 = 11.5 and P/E25 = 32.4) My assumptions: ADMA will be highly profitable due to high ratio of hyperimmunes (maybe eventually they will only manufacture hyperimmunes if S. pneumonia is successful and provided they can source the required amount of hyperimmune plasma).

Key Takeaways Well-diversified drug pipeline with 52 drugs in late-stage approval - a good hedge for its patent expirations Kenvue spin off allows JNJ to focus on its more profitable Medical Devices and Pharmaceuticals segments Continued dividend increases and buybacks are affordable and will help capital returns Post Kenvue, I expect JNJ to grow revenues by 7.5% p.a. from its new baseline of $84B, and at higher margins Some risks around litigation, patent expiry and drug success are present Catalysts Robust Drug Pipeline: 52 Drugs Racing To The Finish Line In Late-Stage Approval The key threat to a pharmaceutical stock is the patent expiration of their high value assets. Should a company lack a product pipeline to bolster its future product portfolio, then losing exclusivity to any one drug can be a hit to the business.